TrialAdvances in therapy2019

Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.

Marilyn K Glassberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.